#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic lymphocytic leukaemia refractory Neurotrophic keratopathy Small intestine adenocarcinoma Primitive neuroectodermal tumour Osteosarcoma Thermal burn Pulmonary arterial hypertension Osteosarcoma recurrent Dupuytren's contracture Autoimmune disorder Germ cell cancer Marginal zone lymphoma recurrent Acute myeloid leukaemia refractory Hypotransferrinaemia Anal squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Factor IX deficiency – Basic Information Von Willebrand’s disease Systemic sclerosis pulmonary – Treatment Langerhans cell sarcoma Paraneoplastic neurological syndrome – Trials in Disease Langerhans cell sarcoma – Trials in Disease Von Willebrand’s disease – Diagnostics Wiskott-Aldrich syndrome – Treatment Friedreich’s ataxia – Life with Disease Encephalitis autoimmune – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lurbinectedin Mva-Hbvac Rilpivirine Ecoo2 Interferon Beta-1A Atorvastatin Al8326 Palonosetron Hydrochloride Olea Europaea Pollen Extract Dermatophagoides Pteronyssinus Varegacestat NADOFARAGENE FIRADENOVEC Zibotentan Ticagrelor Elezanumab Nitrogen Nortriptyline BUMETANIDE Pegfilgrastim Levomepromazine Hydrochloride More therapies…

    Learn about Your Condition

    Liposarcoma recurrent Bladder cancer recurrent Stevens-Johnson syndrome Placenta praevia Bronchopulmonary aspergillosis Eye pain Cough Acute hepatic failure Epilepsy Glucose tolerance impaired Neuropathic arthropathy Laryngeal cancer stage II Varicella Muscle strain Restless legs syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Ziemelkurzemes regionala slimnica SIA

Ziemelkurzemes regionala slimnica SIA

Inzenieru Iela 60, Ventspils, 3601, Latvia

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1

  • Long-Term Study of Imeroprubart in Adults With Graves’ Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Graves’ disease
    Investigated Drugs:
    • IMEROPRUBART
    Belgium Bulgaria Czechia Germany Greece Hungary +5

  • A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Aflibercept
    Bulgaria Czechia Hungary Latvia Poland Slovakia

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

    Not yet recruiting

    4 1 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Poland

  • Study on the Effects of TOUR006 for Adults with Thyroid Eye Disease

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Endocrine ophthalmopathy
    Investigated Drugs:
    • HUMAN IGG2 MONOCLONAL ANTIBODY AGAINST IL-6
    France Italy Latvia Poland Slovakia Spain

  • A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Aflibercept
    • ZUNIBERGENE ROCPARVOVEC
    Bulgaria France Germany Hungary Italy Latvia +3

  • Study of BP05 and Ranibizumab Efficacy and Safety in Patients with Wet Age-Related Macular Degeneration

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Latvia Slovakia

  • Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Endocrine ophthalmopathy
    Investigated Drugs:
    • Batoclimab
    Belgium Germany Hungary Latvia Slovakia Spain

  • Study on Batoclimab for Patients with Thyroid Eye Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Endocrine ophthalmopathy
    Investigated Drugs:
    • Batoclimab
    Belgium Hungary Italy Latvia Poland Slovakia +1

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!